Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer’s Disease

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|15|8|648-658

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.15, Iss.8, 2015-06, pp. : 648-658

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

By Jönsson L.  

PharmacoEconomics, Vol. 21, Iss. 14, 2003-01 ,pp. : 1025-1037

Adis International

Access to resources Recommend Favorite

Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease

By Martinez Ana   Castro Ana  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 1, 2006-01 ,pp. : 1-12

Informa Healthcare

Access to resources Recommend Favorite

The Role of Bridging Studies in the Development of Cholinesterase Inhibitors for Alzheimer’s Disease

By Cutler N.R.   Sramek J.J.  

CNS Drugs, Vol. 10, Iss. 5, 1998-11 ,pp. : 355-364

Adis International

Access to resources Recommend Favorite

GSK-3 inhibitors and their potential in the treatment of Alzheimer’s disease

By Kypta Robert M  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 10, 2005-10 ,pp. : 1315-1331

Informa Healthcare

Access to resources Recommend Favorite

Cholinesterase Inhibitors Used in the Treatment of Alzheimer’s Disease: The Relationship Between Pharmacological Effects and Clinical Efficacy

By Wilkinson D.G.  

Drugs & Aging, Vol. 21, Iss. 7, 2004-01 ,pp. : 453-478

Adis International

Access to resources Recommend Favorite